Skip to main content
SpringerLink
Log in

Super-resistant CAR Ts take on cancers

  • News
  • Published:

From Nature Biotechnology

View current issue Submit your manuscript

Sophisticated genome editing tools to tweak multiple genes in one step are forging a first-of-its-kind generation of universal CAR T therapeutics, while ‘epitope-edited’ and virus-free manufacturing aim to democratize CAR T cells’ clinical uptake worldwide.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Author information

Authors and Affiliations

  1. Somerville, MA, USA

    Elie Dolgin

Authors
  1. Elie Dolgin
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Dolgin, E. Super-resistant CAR Ts take on cancers. Nat Biotechnol 42, 5–7 (2024). https://doi.org/10.1038/s41587-023-02092-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41587-023-02092-0

  • Springer Nature America, Inc.

Search

Navigation